Presentation to highlight advancements in Hoth’s clinical pipeline, including
HT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology program
targeting KIT-driven tumors
NEW YORK, Oct. 7, 2025 — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for dermatological, oncology, and Alzheimer’s, today announced that Chief Executive Officer Robb Knie will be presenting at the upcoming BIO-Europe 2025 Conference, taking place November 3–5, 2025, in Vienna, Austria.
At the conference, Mr. Knie will highlight the Company’s two leading development programs:
-
HT-001 – a topical therapeutic designed to reduce rash and skin toxicity associated with cancer therapies, including EGFR inhibitors and radiotherapy.
-
HT-KIT – a precision oncology program targeting cancers driven by dysregulated KIT signaling.
“BIO-Europe is one of the premier global events for biopharma partnering and innovation,” said Robb Knie, CEO of Hoth Therapeutics. “We look forward to sharing progress on our lead programs and engaging with potential collaborators who share our vision of developing breakthrough therapies for patients with high unmet needs.”
Hoth’s presentation and partnering schedule will be available to registered attendees through the BIO-Europe® partneringONE platform.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .